

The global burden of urinary bladder cancer: an update

World Journal of Urology

38, 1895-1904

DOI: [10.1007/s00345-019-02984-4](https://doi.org/10.1007/s00345-019-02984-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Transurethral needle electrode resection and transurethral holmium laser resection of bladder cancer. <i>World Journal of Surgical Oncology</i> , 2020, 18, 166.	0.8	4
2	<i>Radix Sophorae Flavescentis</i> induces apoptosis through by Caspase, MAPK Activation and ROS Signaling Pathways in 5637 Human Bladder Cancer Cells. <i>International Journal of Medical Sciences</i> , 2020, 17, 1474-1481.	1.1	10
3	Recurrence and progression of non-muscle invasive bladder cancer following trans-urethral resection of bladder tumour with adjuvant intravesical chemo-immunotherapy. <i>Journal of Chitwan Medical College</i> , 2020, 10, 34-38.	0.0	0
4	A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients's Omics Signatures. <i>Cancers</i> , 2020, 12, 3519.	1.7	12
5	NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumourigenesis. <i>Cancers</i> , 2020, 12, 3609.	1.7	44
6	Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 global burden of disease study. <i>BMC Public Health</i> , 2020, 20, 1693.	1.2	12
7	Bladder Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1980.	3.8	817
8	lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System. <i>Cancers</i> , 2020, 12, 2148.	1.7	27
9	Grain and dietary fiber intake and bladder cancer risk: a pooled analysis of prospective cohort studies. <i>American Journal of Clinical Nutrition</i> , 2020, 112, 1252-1266.	2.2	21
10	16-Hydroxycyclohexa-3,13-Dien-15,16-Olone Induces Apoptosis in Human Bladder Cancer Cells through Cell Cycle Arrest, Mitochondria ROS Overproduction, and Inactivation of EGFR-Related Signalling Pathways. <i>Molecules</i> , 2020, 25, 3958.	1.7	9
11	Docosahexaenoic Acid Reverted the All-trans Retinoic Acid-Induced Cellular Proliferation of T24 Bladder Cancer Cell Line. <i>Journal of Clinical Medicine</i> , 2020, 9, 2494.	1.0	5
12	MRADs for Bladder Cancer: Current Applications and Future Developments. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 23-36.	1.9	52
13	The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin. <i>BJU International</i> , 2021, 128, 65-71.	1.3	13
14	Putting the Brakes on Tumorigenesis with Natural Products of Plant Origin: Insights into the Molecular Mechanisms of Actions and Immune Targets for Bladder Cancer Treatment. <i>Cells</i> , 2020, 9, 1213.	1.8	17
15	The Association between Selective Serotonin Reuptake Inhibitors (SSRIs) Use and the Risk of Bladder Cancer: A Nationwide Population-Based Cohort Study. <i>Cancers</i> , 2020, 12, 1184.	1.7	12
16	Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3814.	1.8	15
17	NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?. <i>Nature Reviews Urology</i> , 2020, 17, 491-492.	1.9	5
18	Bladder Cancer Chemosensitivity Is Affected by Paraoxonase-2 Expression. <i>Antioxidants</i> , 2020, 9, 175.	2.2	25

#	ARTICLE	IF	CITATIONS
19	Impact of Matrix Metalloproteinases 11 Gene Variants on Urothelial Cell Carcinoma Development and Clinical Characteristics. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 475.	1.2	6
20	A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection. <i>Frontiers in Oncology</i> , 2020, 9, 1484.	1.3	6
21	Establishment of a bladder cancer cell line expressing both mesenchymal and epithelial lineage-associated markers. <i>Human Cell</i> , 2021, 34, 675-687.	1.2	2
22	Safety and Efficacy of Transurethral Resection of Bladder Tumor Comparing Spinal Anesthesia with Spinal Anesthesia with an Obturator Nerve Block: A Systematic Review and Meta-analysis. <i>Journal of Endourology</i> , 2021, 35, 249-258.	1.1	9
23	Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions. , 2021, 12, 868.		14
24	Histological Characterization of Feline Bladder Urothelial Carcinoma. <i>Journal of Comparative Pathology</i> , 2021, 182, 9-14.	0.1	4
25	Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach. <i>European Radiology</i> , 2021, 31, 3874-3883.	2.3	34
26	Clinical Practice Guidelines for Bladder Cancer: A Systematic Review and Meta-Analysis Using the AGREE II Instrument. <i>Urologia Internationalis</i> , 2021, 105, 31-40.	0.6	8
27	Bladder cancer in the time of machine learning: Intelligent tools for diagnosis and management. <i>Urologia</i> , 2021, 88, 94-102.	0.3	9
28	Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 4036-4050.	0.6	11
29	Epidemiology of Bladder Cancer: Trends and Disparities. , 2021, , 1-12.		0
30	Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging-Reporting and Data System (VI-RADS) performance and potential clinical applications. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110395.	0.9	14
31	Long Noncoding RNAs as Innovative Urinary Diagnostic Biomarkers. <i>Methods in Molecular Biology</i> , 2021, 2292, 73-94.	0.4	4
33	Identification and Immunocorrelation of Prognosis-Related Genes Associated With Development of Muscle-Invasive Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 598599.	1.6	4
34	Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer Therapy. <i>Pharmaceutics</i> , 2021, 13, 166.	2.0	17
35	Resveratrol effects in bladder cancer: A mini review. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200371.	0.6	9
36	Spectrum of Bladder Cancer Patients Morbidity and Mortality in a Tertiary Hospital of Northwestern Nigeria: A 7-Year Review. <i>Open Journal of Urology</i> , 2021, 11, 36-44.	0.0	0
37	Conclusion and Remarks. , 2021, , 249-252.		0

#	ARTICLE	IF	CITATIONS
38	Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues. <i>Cancers</i> , 2021, 13, 813.	1.7	27
39	A potential panel of five mRNAs in urinary extracellular vesicles for the detection of bladder cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 809-820.	0.6	1
40	Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment. <i>Molecules</i> , 2021, 26, 1294.	1.7	13
41	Discovery of Volatile Biomarkers for Bladder Cancer Detection and Staging through Urine Metabolomics. <i>Metabolites</i> , 2021, 11, 199.	1.3	27
42	Vitamin A and Retinoids in Bladder Cancer Chemoprevention and Treatment: A Narrative Review of Current Evidence, Challenges and Future Prospects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3510.	1.8	11
43	Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2800.	1.8	19
44	19-(Benzyloxy)-19-oxojolkinolide B (19-BJB), an ent-abietane diterpene diepoxide, inhibits the growth of bladder cancer T24 cells through DNA damage. <i>PLoS ONE</i> , 2021, 16, e0248468.	1.1	2
45	Oxidative stress in bladder cancer: an ally or an enemy?. <i>Molecular Biology Reports</i> , 2021, 48, 2791-2802.	1.0	9
46	Vegetable intake and the risk of bladder cancer in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study. <i>BMC Medicine</i> , 2021, 19, 56.	2.3	17
47	Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up. <i>World Journal of Urology</i> , 2021, 39, 3329-3335.	1.2	19
48	Bacillus Calmette-Guerin vaccine and bladder cancer incidence: Scoping literature review and preliminary analysis. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 1-8.	0.4	4
49	Cytotoxic Activity of LLO Y406A Is Targeted to the Plasma Membrane of Cancer Urothelial Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3305.	1.8	3
50	Ensemble forecasting of a continuously decreasing trend in bladder cancer incidence in Taiwan. <i>Scientific Reports</i> , 2021, 11, 8373.	1.6	6
51	EPDR1 is related to stages and metastasize in bladder cancer and can be used as a prognostic biomarker. <i>BMC Urology</i> , 2021, 21, 71.	0.6	10
52	Achieving highly efficient gene transfer to the bladder by increasing the molecular weight of polymer-based nanoparticles. <i>Journal of Controlled Release</i> , 2021, 332, 210-224.	4.8	6
53	Arsenic level in bladder tumor of patients from an exposed population: association with progression and prognosis. <i>Future Oncology</i> , 2021, 17, 1311-1323.	1.1	6
54	UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives. <i>Translational Andrology and Urology</i> , 2021, 10, 1908-1917.	0.6	16
55	Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis. <i>BioMed Research International</i> , 2021, 2021, 1-10.	0.9	7

#	ARTICLE	IF	CITATIONS
56	Identification of an 11-Autophagy-Related-Gene Signature as Promising Prognostic Biomarker for Bladder Cancer Patients. <i>Biology</i> , 2021, 10, 375.	1.3	10
57	Artificial intelligence in bladder cancer prognosis: a pathway for personalized medicine. <i>Current Opinion in Urology</i> , 2021, 31, 404-408.	0.9	5
58	The Regulating Effect of Autophagy-Related MiRNAs in Kidney, Bladder, and Prostate Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	0.6	5
59	Transcriptome analyses of urine RNA reveal tumor markers for human bladder cancer: validated amplicons for RT-qPCR-based detection. <i>Oncotarget</i> , 2021, 12, 1011-1023.	0.8	6
60	A bibliometric review of oncolytic virus research as a novel approach for cancer therapy. <i>Virology Journal</i> , 2021, 18, 98.	1.4	10
61	A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection. <i>Bladder Cancer</i> , 2021, 7, 221-241.	0.2	3
62	Biodegradable Controlled-Release Device for Localized Chemotherapeutic Treatment of Bladder Cancer. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 2548-2557.	2.6	4
63	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 97, 102187.	3.4	31
64	Utility of first order MRI-Texture analysis parameters in the prediction of histologic grade and muscle invasion in urinary bladder cancer: a preliminary study. <i>British Journal of Radiology</i> , 2021, 94, 20201114.	1.0	4
65	Incidence trends and survival prediction of urothelial cancer of the bladder: a population-based study. <i>World Journal of Surgical Oncology</i> , 2021, 19, 221.	0.8	4
66	Î²â€Caryophyllene induces apoptosis and inhibits cell proliferation by deregulation of STATâ€3/mTOR/AKT signaling in human bladder cancer cells: An in vitro study. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22863.	1.4	4
67	The Roles of CircRNAs in Bladder Cancer: Biomarkers, Tumorigenesis Drivers, and Therapeutic Targets. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 666863.	1.8	11
68	Reduction in mitochondrial oxidative stress mediates hypoxia-induced resistance to cisplatin in human transitional cell carcinoma cells. <i>Neoplasia</i> , 2021, 23, 653-662.	2.3	11
69	A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy. <i>Future Oncology</i> , 2021, 17, 3987-3994.	1.1	3
70	miR-665 inhibits epithelial-to-mesenchymal transition in bladder cancer via the SMAD3/SNAIL axis. <i>Cell Cycle</i> , 2021, 20, 1242-1252.	1.3	16
71	Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 837-855.	1.9	14
72	Sulforaphane as a potential remedy against cancer: Comprehensive mechanistic review. <i>Journal of Food Biochemistry</i> , 2022, 46, e13886.	1.2	14
73	Predicting bladder cancer prognosis by integrating multi-omics data through a transfer learning-based Cox proportional hazards network. <i>CCF Transactions on High Performance Computing</i> , 2021, 3, 311-319.	1.1	6

#	ARTICLE	IF	CITATIONS
74	Optimization of a floating poloxamer 407-based hydrogel using the Box-Behnken design: in vitro characterization and in vivo buoyancy evaluation for intravesical instillation. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 163, 105885.	1.9	12
75	Quality of Life and Anxiety in Patients with First Diagnosed Non-Muscle Invasive Bladder Cancer Who Receive Adjuvant Bladder Therapy. <i>Bladder Cancer</i> , 2021, 7, 297-306.	0.2	2
76	Blood cell count is not a significant predictor of survival in bladder cancer after radical cystectomy. <i>Universa Medicina</i> , 2021, 40, 151-159.	0.1	0
77	Roles of CCL2-CCR2 Axis in the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8530.	1.8	50
78	Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 705294.	1.3	5
79	Targeting S1PR1 May Result in Enhanced Migration of Cancer Cells in Bladder Carcinoma. <i>Cancers</i> , 2021, 13, 4474.	1.7	4
80	Time to Turn on the Blue Lights: A Systematic Review and Meta-analysis of Photodynamic Diagnosis for Bladder Cancer. <i>European Urology Open Science</i> , 2021, 31, 17-27.	0.2	25
81	Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment. <i>Pharmaceutics</i> , 2021, 13, 1415.	2.0	10
82	Investigation of the roles of IL-18 (-607 C/A) and IL-18 (-137 G/C) gene variations in bladder cancer development: case-control study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3627-3637.	1.2	0
83	CALD1 promotes the expression of PD-L1 in bladder cancer via the JAK/STAT signaling pathway. <i>Annals of Translational Medicine</i> , 2021, 9, 1441-1441.	0.7	13
85	Biomarkers in Bladder Cancer Surveillance. <i>Frontiers in Surgery</i> , 2021, 8, 735868.	0.6	18
86	Testicular Nuclear Receptor 4 Regulates Proliferation and Apoptosis of Bladder Cancer via Bcl-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 670409.	1.6	1
87	Biomarkers for Precision Urothelial Carcinoma Diagnosis: Current Approaches and the Application of Single-Cell Technologies. <i>Cancers</i> , 2021, 13, 260.	1.7	14
89	Making pharmaceutical research and regulation work for women. <i>BMJ, The</i> , 2020, 371, m3808.	3.0	17
91	Polyphyllin II inhibits human bladder cancer migration and invasion by regulating EMT-associated factors and MMPs. <i>Oncology Letters</i> , 2020, 20, 2928-2936.	0.8	22
92	lncRNA CASC9 sponges miR-758-3p to promote proliferation and EMT in bladder cancer by upregulating TGF- β 2. <i>Oncology Reports</i> , 2020, 45, 265-277.	1.2	25
93	Association between perioperative glucocorticoids and cancer metastasis and survival in patients undergoing radical cystectomy for urothelial carcinoma of the bladder: A single-center retrospective study. <i>Investigative and Clinical Urology</i> , 2020, 61, 382.	1.0	4
94	Development of Mitomycin C-Loaded Nanoparticles Prepared Using the Micellar Assembly Driven by the Combined Effect of Hydrogen Bonding and π - π Stacking and Its Therapeutic Application in Bladder Cancer. <i>Pharmaceutics</i> , 2021, 13, 1776.	2.0	6

#	ARTICLE	IF	CITATIONS
95	Identification of a Nuclear Mitochondrial-Related Multi-Genes Signature to Predict the Prognosis of Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 746029.	1.3	8
96	The emerging treatment landscape of advanced urothelial carcinoma. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, Publish Ahead of Print, 247-252.	0.5	1
97	Long Non-coding RNA DANCR in Cancer: Roles, Mechanisms, and Implications. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 753706.	1.8	17
98	Microbiota/microbiome urine and bladder cancer. <i>Onkourologiya</i> , 2020, 16, 97-103.	0.1	1
100	Analysis of urinary kallikrein-related peptidase 13 for monitoring bladder cancer. <i>Biomarkers</i> , 2021, 26, 1-30.	0.9	1
101	Ubiquitination-Related Molecular Subtypes and a Novel Prognostic Index for Bladder Cancer Patients. <i>Pathology and Oncology Research</i> , 2021, 27, 1609941.	0.9	6
102	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 441-450.	3.0	2
103	Urinary Volatiles and Chemical Characterisation for the Non-Invasive Detection of Prostate and Bladder Cancers. <i>Biosensors</i> , 2021, 11, 437.	2.3	22
104	Comprehensive analysis of the functions and prognostic significance of RNA-binding proteins in bladder urothelial carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 7160-7173.	0.0	5
105	COVID-19 impact on bladder cancer-orientations for diagnosing, decision making, and treatment. <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 132-139.	0.4	1
106	Mutations of predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 386-413.	0.3	1
107	Autochthonous male urothelial carcinoma immune competent model: from induction to BCG transurethral treatment. <i>International Journal of Clinical and Experimental Pathology</i> , 2021, 14, 980-986.	0.5	0
108	Diagnostic benefit of multiparametric MRI over contrast-enhanced CT in patients with bladder cancer: A single-center 1-year experience. <i>European Journal of Radiology</i> , 2022, 146, 110059.	1.2	2
109	Molecular Pathways in Low and High-grade Non-muscle Invasive Bladder Cancer as Revealed by Several OMICs Data Analyses. , 2021, 1, .		0
110	Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990â€“2019. <i>Military Medical Research</i> , 2021, 8, 60.	1.9	47
111	The human TRAM1 locus expresses circular RNAs. <i>Scientific Reports</i> , 2021, 11, 22114.	1.6	0
112	Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease study 2019. <i>BMJ Global Health</i> , 2021, 6, e004128.	2.0	41
113	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 710943.	1.6	6

#	ARTICLE	IF	CITATIONS
114	Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients. <i>Cancers</i> , 2021, 13, 5841.	1.7	12
115	The impact of 18F-fluorodeoxyglucose PET/computed tomography on clinical staging in bladder cancer. <i>Nuclear Medicine Communications</i> , 2022, 43, 172-176.	0.5	0
116	circKDM4C enhances bladder cancer invasion and metastasis through miR-200bc-3p/ZEB1 axis. <i>Cell Death Discovery</i> , 2021, 7, 365.	2.0	15
117	Identification of Immune-Related Genes Associated With Bladder Cancer Based on Immunological Characteristics and Their Correlation With the Prognosis. <i>Frontiers in Genetics</i> , 2021, 12, 763590.	1.1	7
118	Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-7.	1.1	3
119	Embelin: A novel XIAP inhibitor for the prevention and treatment of chronic diseases. <i>Journal of Biochemical and Molecular Toxicology</i> , 2022, 36, e22950.	1.4	11
120	Dietary patterns and risk of bladder cancer: a systematic review and meta-analysis. <i>BMC Public Health</i> , 2022, 22, 73.	1.2	12
121	Reasoning about bladder cancer treatment outcomes using clinical trials within a knowledge-based clinical evidence approach. <i>Procedia Computer Science</i> , 2022, 196, 631-639.	1.2	1
122	Qici Sanling Decoction Suppresses Glutamine Consumption and Bladder Cancer Cell Growth through Inhibiting c-Myc Expression. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	3
123	EZH2 targeting to improve the sensitivity of acquired radio-resistance bladder cancer cells. <i>Translational Oncology</i> , 2022, 16, 101316.	1.7	9
124	MicroRNA-582-5p regulates cell invasion in bladder cancer through targeting Forkhead Box G1. <i>Pathology Research and Practice</i> , 2022, 230, 153752.	1.0	2
125	Ferroptosis Mediation Patterns Reveal Novel Tool to Implicate Immunotherapy and Multi-Omics Characteristics in Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 791630.	1.8	6
126	Concise synthesis and biological activity evaluation of novel pyrazinylâ€‘aryl urea derivatives against several cancer cell lines, which can especially induce T24 apoptotic and necroptotic cell death. <i>RSC Medicinal Chemistry</i> , 2022, 13, 280-299.	1.7	1
127	Diagnostic panel of serum miR-125b-5p, miR-182-5p, and miR-200c-3p as non-invasive biomarkers for urothelial bladder cancer. <i>Clinical and Translational Oncology</i> , 2022, 24, 909.	1.2	3
128	Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway. <i>Nutrients</i> , 2022, 14, 369.	1.7	4
129	MIR100HG Regulates CALD1 Gene Expression by Targeting miR-142-5p to Affect the Progression of Bladder Cancer Cells in vitro, as Revealed by Transcriptome Sequencing. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 793493.	1.6	10
130	Mycobacterium bovis bacille Calmetteâ€‘Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy. <i>Clinical and Experimental Medicine</i> , 2023, 23, 519-527.	1.9	1
131	Novel dihydroartemisinin derivative Mito-DHA5 induces apoptosis associated with mitochondrial pathway in bladder cancer cells. <i>BMC Pharmacology & Toxicology</i> , 2022, 23, 10.	1.0	3

#	ARTICLE	IF	CITATIONS
132	Alteration in glycolytic/cholesterogenic gene expression is associated with bladder cancer prognosis and immune cell infiltration. <i>BMC Cancer</i> , 2022, 22, 2.	1.1	7
133	Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer. <i>European Urology Open Science</i> , 2022, 35, 29-36.	0.2	2
134	Role of Long Non-Coding RNA LINC00641 in Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 829137.	1.3	6
135	Development of a CAFs-related gene signature to predict survival and drug response in bladder cancer. <i>Human Cell</i> , 2022, 35, 649-664.	1.2	11
136	Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 507-521.	2.0	7
137	Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. <i>Biomedicines</i> , 2022, 10, 411.	1.4	11
138	Socio-economic burden of disease: Survivorship costs for bladder cancer. <i>Journal of Cancer Policy</i> , 2022, 32, 100326.	0.6	13
139	Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 757432.	1.2	5
140	An Unfolded Protein Response Related Signature Could Robustly Predict Survival Outcomes and Closely Correlate With Response to Immunotherapy and Chemotherapy in Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 780329.	1.6	5
141	Urothelkarzinom der Harnblase: Epidemiologie, Ätiologie und Risikofaktoren. <i>Springer Reference Medizin</i> , 2022, , 1-7.	0.0	0
142	Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS. <i>BMC Cancer</i> , 2022, 22, 214.	1.1	18
143	Clinical Applications and Anticancer Effects of Antimicrobial Peptides: From Bench to Bedside. <i>Frontiers in Oncology</i> , 2022, 12, 819563.	1.3	39
144	Fatty Acid Binding Protein 6 Inhibition Decreases Cell Cycle Progression, Migration and Autophagy in Bladder Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2154.	1.8	6
145	Three-Dimensional Ultrasound Images in the Assessment of Bladder Tumor Health Monitoring under Deep Learning Algorithms. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-10.	0.7	4
146	Tea consumption and risk of bladder cancer in the Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) Study: Pooled analysis of 12 international cohort studies. <i>Clinical Nutrition</i> , 2022, 41, 1122-1130.	2.3	12
147	Vegetable and fruit intake and the risk of bladder cancer: Japan Public Health Center-based prospective study. <i>British Journal of Cancer</i> , 2022, 126, 1647-1658.	2.9	4
148	Correlating Dietary Pattern and Bladder Cancer Risk Using Principal Component and Reduced Rank Regression Analyses. <i>Nutrition and Cancer</i> , 2022, , 1-9.	0.9	2
149	Efficacy of pre and rehabilitation in radical cystectomy on health related quality of life and physical function: A systematic review. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2022, 9, 100046.	0.7	5

#	ARTICLE	IF	CITATIONS
150	Ferroptosis Patterns and Tumor Microenvironment Infiltration Characterization in Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 832892.	1.8	17
151	When to Avoid a Restaging Procedure for Non-muscle Invasive Bladder Cancer? Inferences from a Tertiary Care Center. <i>Indian Journal of Surgical Oncology</i> , 0, , 1.	0.3	1
152	Global analysis of miRNA-mRNA regulation pair in bladder cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, 66.	0.8	3
153	Effect of statins on risk and mortality of urologic malignancies: Protocol of an umbrella review. <i>PLoS ONE</i> , 2022, 17, e0264076.	1.1	1
154	Increased One-Year Mortality Among Elderly Patients After Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective, Observational Comparative Study. <i>Clinical Interventions in Aging</i> , 2022, Volume 17, 255-263.	1.3	2
155	Comparison of urinary telomerase, CD44, and NMP22 assays for detection of bladder squamous cell carcinoma. <i>Current Urology</i> , 2022, Publish Ahead of Print, .	0.4	0
156	5-Methylcytosine-Related Long Noncoding RNAs Are Potential Biomarkers to Predict Overall Survival and Regulate Tumor-Immune Environment in Patients with Bladder Cancer. <i>Disease Markers</i> , 2022, 2022, 1-26.	0.6	3
157	Impact of Circadian Rhythms on the Development and Clinical Management of Genitourinary Cancers. <i>Frontiers in Oncology</i> , 2022, 12, 759153.	1.3	5
158	Conspicuity and muscle-invasiveness assessment for bladder cancer using VI-RADS: a multi-reader, contrast-free MRI study to determine optimal b-values for diffusion-weighted imaging. <i>Abdominal Radiology</i> , 2022, 47, 1862-1872.	1.0	4
159	SUMOylation Pattern Predicts Prognosis and Indicates Tumor Microenvironment Infiltration Characterization in Bladder Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 864156.	2.2	11
160	Proteomics for Early Detection of Non-Muscle-Invasive Bladder Cancer: Clinically Useful Urine Protein Biomarkers. <i>Life</i> , 2022, 12, 395.	1.1	7
161	Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	0.7	5
162	Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2904.	1.8	7
163	Metformin Use on Incidence and Oncologic Outcomes of Bladder Cancer Patients With T2DM: An Updated Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, 865988.	1.6	3
164	Curcumin May Prevent Basement Membrane Disassembly by Matrix Metalloproteinases and Progression of the Bladder Cancer. <i>Nutrients</i> , 2022, 14, 32.	1.7	9
165	Comparison of the diagnostic accuracy and validity of biparametric MRI and multiparametric MRI-based VI-RADS scoring in bladder cancer; is contrast material really necessary in detecting muscle invasion?. <i>Abdominal Radiology</i> , 2022, 47, 771-780.	1.0	12
166	A long noncoding RNA GTF2IRD2P1 suppresses cell proliferation in bladder cancer by inhibiting the Wnt/ β -catenin signaling pathway. <i>PeerJ</i> , 2022, 10, e13220.	0.9	4
167	Editorial: Recent Advances in Bladder Cancer Diagnosis and Treatment. <i>Frontiers in Surgery</i> , 2022, 9, 890172.	0.6	1

#	ARTICLE	IF	CITATIONS
169	New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103682.	2.0	5
172	Linc00662 plays an oncogenic role in bladder cancer by sponging miR-199a-5p.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 12673-12683.	0.0	0
173	Characterization of the Peri-Membrane Fluorescence Phenomenon Allowing the Detection of Urothelial Tumor Cells in Urine. <i>Cancers</i> , 2022, 14, 2171.	1.7	1
174	A clinical case of a big urethral recurrence after cystectomy in a patient with invasive bladder cancer. <i>AlĖmanah KliniĖeskoj Mediciny</i> , 2022, 50, 71-75.	0.2	0
175	SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling. <i>British Journal of Cancer</i> , 2022, 127, 211-222.	2.9	14
176	Development, regeneration and tumorigenesis of the urothelium. <i>Development (Cambridge)</i> , 2022, 149, .	1.2	6
177	M2 Tumor Associate Macrophage- (TAM-) Derived lncRNA HISLA Promotes EMT Potential in Bladder Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	0.6	0
178	Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses. <i>Journal of Infusion Nursing</i> , 2022, 45, 142-153.	1.2	2
179	CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5453.	1.8	7
180	¹³ C Natural Isotope Abundance in Urothelium as a New Marker in the Follow-Up of Patients with Bladder Cancer. <i>Cancers</i> , 2022, 14, 2423.	1.7	5
181	Oncologic outcomes of Bacillus Calmette-GuĖrin therapy in elderly patients with non-muscle-invasive bladder cancer: A meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0267934.	1.1	0
182	Epidemiological and Clinical Aspects of Bladder Tumours at the Nianankoro Fomba Hospital in Segou in the Urology Department. <i>Open Journal of Urology</i> , 2022, 12, 294-303.	0.0	1
183	Bladder Cancer and Fluorescence Cystoscopy. , 2022, 12, .		0
184	Modified Titanium Dioxide as a Potential Visible-Light-Activated Photosensitizer for Bladder Cancer Treatment. <i>ACS Omega</i> , 2022, 7, 17563-17574.	1.6	2
185	Peripheral T-Cell Lymphoma of Urinary Bladder Presenting With Just Irritative Voiding Symptoms. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 133-137.	0.1	0
186	Urothelial Bladder Carcinoma in Students at a Dental Technical College: A Report of 3 Cases. <i>Case Reports in Oncology</i> , 0, , 553-559.	0.3	0
187	Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2022, , 1-14.	0.2	0
188	Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 490.e13-490.e20.	0.8	19

#	ARTICLE	IF	CITATIONS
189	Transurethral Resection of Bladder Tumours: Results and Outcomes. Open Journal of Urology, 2022, 12, 342-356.	0.0	0
190	Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer. Frontiers in Oncology, 0, 12, .	1.3	5
191	Comparative Analysis of Elderly Patients Undergoing Radical Cystectomy With Ureterocutaneostomy or Ileal Conduit With a Special Focus on Bowl Complications Requiring Surgical Revision. Frontiers in Surgery, 0, 9, .	0.6	3
192	Tannic acid attenuate AKT phosphorylation to inhibit UMUC3 bladder cancer cell proliferation. Molecular and Cellular Biochemistry, 2022, 477, 2863-2869.	1.4	2
193	Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatmentâ€”A Retrospective Multicenter Analysis. Cancers, 2022, 14, 2850.	1.7	3
194	<i>Metadherin</i> Promotes the Development of Bladder Cancer by Enhancing Cell Division. Cancer Biotherapy and Radiopharmaceuticals, 0, , .	0.7	1
195	Implications of Chromatin Modifier Mutations in Epigenetic Regulation of Bladder Cancer. , 0, , 45-60.		1
196	Metabolic Profiling of Bladder Cancer Patientsâ€™ Serum Reveals Their Sensitivity to Neoadjuvant Chemotherapy. Metabolites, 2022, 12, 558.	1.3	8
197	Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-Î² signalling pathway. Bioengineered, 2022, 13, 14282-14298.	1.4	7
198	Prognosis Analysis and Perioperative Research of Elderly Patients with Non-Muscle-Invasive Bladder Cancer under Computed Tomography Image of Three-Dimensional Reconstruction Algorithm. Contrast Media and Molecular Imaging, 2022, 2022, 1-9.	0.4	0
200	Predictive value of GATA3 and Ki-67 expression in biopsy and transurethral resection specimens in patients with urothelial carcinoma of the urinary bladder. Srpski Arhiv Za Celokupno Lekarstvo, 2022, 150, 525-532.	0.1	0
201	A new survival model based on ferroptosis-related genes (FRGS) for prognostic prediction in bladder cancer. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2022, , .	0.2	4
202	Exploring solid-phase proximity ligation assay for survivin detection in urine. PLoS ONE, 2022, 17, e0270535.	1.1	1
203	Cancer mortality and predictions for 2022 in selected Australasian countries, Russia, and Ukraine with a focus on colorectal cancer. European Journal of Cancer Prevention, 0, Publish Ahead of Print, .	0.6	3
204	Highly Expressed <i>LINC00958</i> Modulates the Growth and Epithelial-Mesenchymal Transition of Bladder Cancer Cells Through <i>SAPK/JNK</i> Signaling Pathway. Cancer Biotherapy and Radiopharmaceuticals, 0, , .	0.7	2
205	Detection of Epithelial-Mesenchymal Transition Markers in High Grade Bladder Cancer and Special Variants of Urothelial Carcinoma. Asian Pacific Journal of Cancer Prevention, 2022, 23, 2079-2087.	0.5	0
206	Hydraulic Detrusor for Artificial Bladder Active Voiding. Soft Robotics, 2023, 10, 269-279.	4.6	5
207	Endoscopic laser en bloc removal of bladder tumor. Surgical radicality and improvement of the pathological diagnostic accuracy. Archivio Italiano Di Urologia Andrologia, 2022, 94, 134-137.	0.4	4

#	ARTICLE	IF	CITATIONS
208	Advances in Diagnosis and Therapy for Bladder Cancer. <i>Cancers</i> , 2022, 14, 3181.	1.7	16
209	Usefulness of the Urine Methylation Test (Bladder EpiCheck®) in Follow-Up Patients with Non-Muscle Invasive Bladder Cancer and Cytological Diagnosis of Atypical Urothelial Cells: An Institutional Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3855.	1.0	5
210	A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
211	Sex differences in treatment patterns for non-advanced muscle-invasive bladder cancer: a descriptive analysis of 3484 patients of the Netherlands Cancer Registry. <i>World Journal of Urology</i> , 2022, 40, 2275-2281.	1.2	7
212	The Relationship of Pyroptosis-Related Genes, Patient Outcomes, and Tumor-Infiltrating Cells in Bladder Urothelial Carcinoma (BLCA). <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
213	Prognostic value and potential biological functions of ferroptosis-related gene signature in bladder cancer. <i>Oncology Letters</i> , 2022, 24, .	0.8	3
215	Pyroptosis-Related Gene to Construct Prognostic Signature and Explore Immune Microenvironment and Immunotherapy Biomarkers in Bladder Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
216	Bladder Tissue Microbiome Composition in Patients of Bladder Cancer or Benign Prostatic Hyperplasia and Related Human Beta Defensin Levels. <i>Biomedicines</i> , 2022, 10, 1758.	1.4	5
217	Bacteria for Treatment: Microbiome in Bladder Cancer. <i>Biomedicines</i> , 2022, 10, 1783.	1.4	4
218	Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer. <i>Cell Cycle</i> , 2022, 21, 2533-2549.	1.3	2
219	Perceived Unmet Needs in Patients Living With Advanced Bladder Cancer and Their Caregivers: Infodemiology Study Using Data From Social Media in the United States. <i>JMIR Cancer</i> , 2022, 8, e37518.	0.9	3
220	Autophagy blockade potentiates cancer-associated immunosuppression through programmed death ligand-1 upregulation in bladder cancer. <i>Journal of Cellular Physiology</i> , 2022, 237, 3587-3597.	2.0	8
221	Nanodiamonds as Possible Tools for Improved Management of Bladder Cancer and Bacterial Cystitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8183.	1.8	7
222	Multiparametric Classification of Non-Muscle Invasive Papillary Urothelial Neoplasms: Combining Morphological, Phenotypical, and Molecular Features for Improved Risk Stratification. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8133.	1.8	4
223	Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
224	5-Aminolevulinic acid-based photodynamic diagnosis for detection of urothelial carcinoma cells in bladder washing sediment suspension: A pilot study. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 40, 103072.	1.3	0
225	Multiple Cancer Combating by Natural Bioactives: A Review. <i>Current Cancer Therapy Reviews</i> , 2022, 18, .	0.2	0
226	Association of Dietary Approaches to Stop Hypertension diet and risk of bladder cancer: A case-control study. <i>European Journal of Cancer Care</i> , 2022, 31, .	0.7	2

#	ARTICLE	IF	CITATIONS
227	Risk of cardiovascular disease among cancer survivors: Protocol of a pooled analysis of population-based cohort studies. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
228	The Role of the Key Differentially Mutated Gene FGFR3 in the Immune Microenvironment of Bladder Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-17.	0.9	2
229	Diagnostic Potential of Circulating Tumor Cells, Urinary MicroRNA, and Urinary Cell-Free DNA for Bladder Cancer: A Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9148.	1.8	11
230	Comprehensive analysis of the endoplasmic reticulum stress-related long non-coding RNA in bladder cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
231	Cardiovascular Mortality Risk in Patients with Bladder Cancer: A Population-Based Study. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 255.	0.8	1
232	Preoperative Free Ferrous Protoporphyrin and Reactive Oxygen Species Status of Voided Urine Predicts Potential Recurrence Risk in NMIBC. <i>Cancer Management and Research</i> , 0, Volume 14, 2291-2297.	0.9	3
233	Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.9	5
234	Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	86
236	Identification and analysis of microRNA editing events in recurrent bladder cancer based on RNA sequencing: MicroRNA editing level is a potential novel biomarker. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
237	Radiomics for the Prediction of Overall Survival in Patients with Bladder Cancer Prior to Radical Cystectomy. <i>Cancers</i> , 2022, 14, 4449.	1.7	8
238	Immunotherapy for Bladder Cancer: Latest Advances and Ongoing Clinical Trials. <i>Immunological Investigations</i> , 2022, 51, 2226-2251.	1.0	14
239	Chronic exposure to microcystin-leucine-arginine induces epithelial hyperplasia and inflammation in the mouse bladder. <i>Ecotoxicology and Environmental Safety</i> , 2022, 244, 114033.	2.9	3
240	Curcumin in the treatment of urological cancers: Therapeutic targets, challenges and prospects. <i>Life Sciences</i> , 2022, 309, 120984.	2.0	14
241	Step-by-Step Approach to Robot-Assisted Female Cystectomy, Anterior Exenteration, and Pelvic Organ Preserving Approaches. , 2022, , 647-660.		0
242	Hsa_circ_0003221 facilitates the malignant development of bladder cancer cells via resulting in the upregulation of DHCR24 by targeting miR-892b. <i>Investigative and Clinical Urology</i> , 2022, 63, 577.	1.0	3
243	Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	7
244	Construction and Validation of an RNA-Binding Protein-Related Bladder Cancer Prognostic Model Based on Bioinformatics. <i>Yangtze Medicine</i> , 2022, 06, 66-75.	0.1	0
245	Introduction to various types of cancers. , 2022, , 1-29.		2

#	ARTICLE	IF	CITATIONS
246	High-Grade Urothelial Carcinoma with Squamous Differentiation and Favourable Response to Immunotherapy – a Case Report. <i>Journal of Medical & Radiation Oncology</i> , 2022, 2, 57-61.	0.0	0
247	A Systematic Review on the Role of Repeat Transurethral Resection after Initial en Bloc Resection for Non-Muscle Invasive Bladder Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 5049.	1.0	4
248	Disseminated Intravascular Coagulation with Enhanced Fibrinolysis Caused by Heart Metastasis of Bladder Urothelial Carcinoma. <i>Case Reports in Oncology</i> , 2022, 15, 745-749.	0.3	2
249	Ferroptosis-Related Long Noncoding RNAs Have Excellent Predictive Ability for Multiomic Characteristics of Bladder Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-30.	1.9	8
250	Bladder tumor Resection Weight as a Prognostic Factor for Recurrence and Progression in Patients With High-Risk Non-Muscle Invasive Bladder Treated With BCG. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e70-e77.	0.9	0
251	Properties of flavonoids in the treatment of bladder cancer (Review). <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	5
252	Immune status for monitoring and treatment of bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
253	State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer. <i>Biosensors</i> , 2022, 12, 796.	2.3	11
254	Glabridin inhibits urothelial bladder carcinoma cell growth <i>in vitro</i> and <i>in vivo</i> by inducing cell apoptosis and cell cycle arrest. <i>Chemical Biology and Drug Design</i> , 2023, 101, 581-592.	1.5	3
255	Mucoadhesive Polymers and Their Applications in Drug Delivery Systems for the Treatment of Bladder Cancer. <i>Gels</i> , 2022, 8, 587.	2.1	15
256	Efficacy of compound aluminum sulfate injection as a monotherapeutic regimen in non-muscle invasive bladder cancer patients: a retrospective single-arm cohort study. <i>Translational Andrology and Urology</i> , 2022, 11, 1292-1303.	0.6	0
257	Comprehensive analysis of cuproptosis-related long noncoding RNA immune infiltration and prediction of prognosis in patients with bladder cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	11
258	STAT3 and Its Pathways – Underestimated Role in Urological Tumors. <i>Cells</i> , 2022, 11, 3024.	1.8	8
259	Femoral metastasis in previously treated bladder cancer patient: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	1
260	A novel T-cell proliferation-associated regulator signature pre-operatively predicted the prognostic of bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
261	Susceptibility Loci in SLC15A1, UGT1A3, and CWC27 Genes Associated with Bladder Cancer in the Northeast Chinese Population. <i>BioMed Research International</i> , 2022, 2022, 1-7.	0.9	2
262	EPDR1 levels and tumor budding predict and affect the prognosis of bladder carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
263	Radical cystectomy and urinary diversion in women: techniques, outcomes, and challenges – a narrative review. <i>Translational Andrology and Urology</i> , 2022, 11, 1598-1610.	0.6	6

#	ARTICLE	IF	CITATIONS
264	Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada. <i>Current Oncology</i> , 2022, 29, 7587-7597.	0.9	4
265	Clinicopathological characteristics and outcomes of synchronous renal cell carcinoma and urothelial carcinoma: A population-based analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
266	Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinomaâ€”A Cost-Effectiveness Analysis. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	1
267	The association between human papillomavirus and bladder cancer: Evidence from metaâ€”analysis and twoâ€”sample mendelian randomization. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	15
268	Genetic susceptibility of bladder cancer in the Lebanese population. <i>BMC Medical Genomics</i> , 2022, 15, .	0.7	1
269	Review on the Discovery of New Benzimidazole Derivatives as Anticancer Agents: Synthesis and Structure-activity Relationship (2010-2022). <i>Letters in Drug Design and Discovery</i> , 2024, 21, 451-479.	0.4	0
270	Predicting Recurrence of Non-Muscle-Invasive Bladder Cancer: Current Techniques and Future Trends. <i>Cancers</i> , 2022, 14, 5019.	1.7	5
271	A global, regional, and national survey on burden and Quality of Care Index (QCI) of bladder cancer: The global burden of disease study 1990â€”2019. <i>PLoS ONE</i> , 2022, 17, e0275574.	1.1	2
272	Ferroptosis: A new therapeutic target for bladder cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
273	Causes of death in female patients with bladder cancer after local tumor excision and radical cystectomy: a contemporary, US population-based analysis. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	0
274	Luminophore Chemistry for Detection of Urinary Bladder Cancer â€” Comparison to Cytology and Urinary Rapid Tests (BTA stat ^{Â®} , NMP22 ^{Â®} BladderChek ^{Â®} and Tj ETQq0 0015gBT /Overlock 10	0.5	0
275	LogP of N-acyl-gemcitabine and lectin-corona emerge as key parameters in nanoparticulate intravesical cancer therapy. <i>European Journal of Pharmaceutical Sciences</i> , 2023, 180, 106330.	1.9	3
276	Hyaluronic Acid Modified Au@SiO2@Au Nanoparticles for Photothermal Therapy of Genitourinary Tumors. <i>Polymers</i> , 2022, 14, 4772.	2.0	7
277	Temporal Trends and Projections of Bladder Cancer Burden in China from 1990 to 2030: Findings from the Global Burden of Disease Study. <i>Clinical Epidemiology</i> , 0, Volume 14, 1305-1315.	1.5	7
278	Genetically supported causality between benign prostate hyperplasia and urinary bladder neoplasms: A mendelian randomization study. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
279	Comparison of different methods of obturator nerve block in transurethral resection of bladder tumors: A systematic review and network metaâ€”analysis. <i>Cancer Medicine</i> , 2023, 12, 5420-5435.	1.3	2
280	A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
281	Translocation of nuclear chromatin distribution to the periphery reflects dephosphorylated threonine-821/826 of the retinoblastoma protein (pRb) in T24 cells treated with Bacillus Calmetteâ€”GuÃ©rin. <i>Cytotechnology</i> , 0, , .	0.7	0

#	ARTICLE	IF	CITATIONS
282	Global research trends in non-muscle invasive bladder cancer: Bibliometric and visualized analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
283	Metabolic syndrome and bladder carcinoma â A cross-sectional study. , 2022, 1, 69.		0
284	KLHL21/CYLD signaling confers aggressiveness in bladder cancer through inactivating NF- κ B signaling. <i>International Immunopharmacology</i> , 2023, 114, 109202.	1.7	1
285	Global changes in bladder cancer mortality in the elderly. <i>Cancer Epidemiology</i> , 2023, 82, 102294.	0.8	1
286	Recent Progress in Urothelial Bladder Carcinoma: Basic Biology, Molecular Characterization, Conventional and Innovative Therapies and TumourâStroma Interactions. , 2022, , .		0
287	Hyperbaric oxygen enhanced the chemotherapy of mitochondrial targeting molecule IR-780 in bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 683-699.	1.2	2
288	Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects. <i>Journal of Clinical Medicine</i> , 2022, 11, 6997.	1.0	1
289	Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 177-195.	0.9	1
290	Adherence to Mediterranean-Style Dietary Pattern and Risk of Bladder Cancer: A Case-Control Study in Iran. <i>Nutrition and Cancer</i> , 0, , 1-8.	0.9	0
291	Fibronectin 1 as a Key Gene in the Genesis and Progression of Cadmium-Related Bladder Cancer. <i>Biological Trace Element Research</i> , 2023, 201, 4349-4359.	1.9	5
292	The Epitope Basis of Embryonic Stem CellâInduced Antitumor Immunity against Bladder Cancer. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	1
294	Pharmacological Activities and Pharmacokinetics of Glycycoumarin. <i>Revista Brasileira De Farmacognosia</i> , 2023, 33, 471-483.	0.6	2
296	UROSCAN and UROSCANSEQ: a large-scale multicenter effort towards translation of molecular bladder cancer subtypes into clinical practice â from biobank to RNA-sequencing in real time. <i>Scandinavian Journal of Urology</i> , 0, , 1-8.	0.6	2
298	Six potential biomarkers for bladder cancer: key proteins in cell-cycle division and apoptosis pathways. <i>Journal of the Egyptian National Cancer Institute</i> , 2022, 34, .	0.6	0
299	Meat Intake and the Risk of Bladder Cancer: A Systematic Review and Meta-Analysis of Observational Studies. <i>Nutrition and Cancer</i> , 2023, 75, 825-845.	0.9	2
300	Posterior quadratus lumborum block versus epidural analgesia for postoperative pain management after open radical cystectomy: A randomized clinical trial. <i>Acta Anaesthesiologica Scandinavica</i> , 2023, 67, 347-355.	0.7	3
301	Chronological Change in EPHA2 Protein Expression Is Associated With Recurrence of Bladder Cancer. <i>Anticancer Research</i> , 2022, 42, 5783-5794.	0.5	1
302	ADAM12 promotes gemcitabine resistance by activating EGFR signaling pathway and induces EMT in bladder cancer. <i>Clinical and Translational Oncology</i> , 2023, 25, 1425-1435.	1.2	6

#	ARTICLE	IF	CITATIONS
303	Changes in muscular wall of artificial bladder in experiment. <i>Klinichna Khirurgiia</i> , 2022, 89, 69-72.	0.0	0
304	A Brief Review of Artificial Intelligence in Genitourinary Oncological Imaging. <i>Canadian Association of Radiologists Journal</i> , 2023, 74, 534-547.	1.1	3
305	Polymorphisms of Antioxidant Enzymes SOD2 (rs4880) and GPX1 (rs1050450) Are Associated with Bladder Cancer Risk or Its Aggressiveness. <i>Medicina (Lithuania)</i> , 2023, 59, 131.	0.8	8
306	Predictive nomograms for early death in metastatic bladder cancer. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	1
307	Kidney functions and electrolyte disturbance among Iraqi patients with bladder cancer. <i>Journal of the Faculty of Medicine, Baghdad</i> , 2023, 64, .	0.1	0
308	Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin $\alpha 5/\beta 1$ -FAK/Src axis: A novel strategy for drug application. <i>Pharmacological Research</i> , 2023, 188, 106654.	3.1	8
309	Bioinformatics analysis of prognosis and immune microenvironment of immunological cell death-related gemcitabine-resistance genes in bladder cancer. <i>Translational Andrology and Urology</i> , 2022, 11, 1715-1728.	0.6	2
310	Urothelial bladder cancer in young age group: Presentation, clinical behavior and outcome. <i>Iraq Medical Journal</i> , 2022, 6, .	0.0	0
311	An angiogenesis-related lncRNA signature for the prognostic prediction of patients with bladder cancer and LINC02321 promotes bladder cancer progression via the VEGFA signaling pathway. <i>Molecular Medicine Reports</i> , 2022, 27, .	1.1	5
312	Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer. <i>Health and Quality of Life Outcomes</i> , 2022, 20, .	1.0	0
313	Molecular Detection of Epstein-Barr virus in Biopsy Samples of Patients Suffering from Bladder Cancer in Bushehr Province, Iran. <i>Iranian South Medical Journal</i> , 2022, 25, 326-339.	0.2	0
314	Performance of Node-RADS Scoring System for a Standardized Assessment of Regional Lymph Nodes in Bladder Cancer Patients. <i>Cancers</i> , 2023, 15, 580.	1.7	4
315	Preclinical-grade microendoscope for optical coherence tomography and angiography inside the bladder. <i>Journal of Optical Microsystems</i> , 2023, 3, .	0.9	0
316	Mendelian randomization investigation identified the causal relationship between body fat indexes and the risk of bladder cancer. <i>PeerJ</i> , 0, 11, e14739.	0.9	1
317	A novel bidirectional perfusion-like administered system for NIR-II fluorescence imaging precision diagnosis of bladder cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2023, 49, 102661.	1.7	3
318	Facile biosynthesis of CaO nanoparticles using extract of <i>Tulbaghia violacea</i> and evaluation of their antibacterial and cytotoxicity activity. <i>Inorganic Chemistry Communication</i> , 2023, 151, 110581.	1.8	2
319	Electrochemical immunosensor utilizing a multifunctional 3D nanocomposite coating with antifouling capability for urinary bladder cancer diagnosis. <i>Sensors and Actuators B: Chemical</i> , 2023, 384, 133621.	4.0	8
320	miRNAs role in bladder cancer pathogenesis and targeted therapy: Signaling pathways interplay – A review. <i>Pathology Research and Practice</i> , 2023, 242, 154316.	1.0	52

#	ARTICLE	IF	CITATIONS
321	Targeting the anaphase-promoting complex/cyclosome (APC/C) enhanced antiproliferative and apoptotic response in bladder cancer. Saudi Journal of Biological Sciences, 2023, 30, 103564.	1.8	1
322	Proteomics strategies for urothelial bladder cancer diagnosis, prognosis and treatment: Trends for tumor biomarker sources. Analytical Biochemistry, 2023, 666, 115074.	1.1	3
323	Novel Zebrafish Patient-Derived Tumor Xenograft Methodology for Evaluating Efficacy of Immune-Stimulating BCG Therapy in Urinary Bladder Cancer. Cells, 2023, 12, 508.	1.8	4
324	Research Progress on Different Urinary Diversion Methods after Radical Bladder Cancer Surgery. Advances in Clinical Medicine, 2023, 13, 1404-1409.	0.0	0
325	Bladder Perforation during Transurethral Resection of Bladder Tumor Is Not an Innocent Accident: Literature Review Based on a Clinical Case Experience. Open Journal of Urology, 2023, 13, 49-54.	0.0	0
326	Radical cystectomy and urinary diversion in women. Translational Andrology and Urology, 2023, 12, 155-157.	0.6	0
327	Nanoparticle-Based Techniques for Bladder Cancer Imaging: A Review. International Journal of Molecular Sciences, 2023, 24, 3812.	1.8	1
328	Differentially Expressed Genes and Molecular Susceptibility to Human Age-Related Diseases. International Journal of Molecular Sciences, 2023, 24, 3996.	1.8	3
329	The trend of schistosomiasis related bladder cancer in the lake zone, Tanzania: a retrospective review over 10Âyears period. Infectious Agents and Cancer, 2023, 18, .	1.2	2
330	Urineâ€based liquid biopsy in bladder cancer: Opportunities and challenges. Clinical and Translational Discovery, 2023, 3, .	0.2	4
332	Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 326.e1-326.e8.	0.8	1
333	Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review. Pharmacoeconomics, 2023, 41, 633-650.	1.7	1
334	Expression pattern, tumor immune landscape, and prognostic value of N7â€methylguanosine regulators in bladder urothelial carcinoma. Oncology Letters, 2023, 25, .	0.8	1
335	The Short- and Long-Term Effect of Radical Cystectomy in Frail Patients With Bladder Cancer. Clinical Genitourinary Cancer, 2023, 21, e291-e298.	0.9	3
336	Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nature Reviews Clinical Oncology, 2023, 20, 287-304.	12.5	34
337	Kawain Inhibits Urinary Bladder Carcinogenesis through Epigenetic Inhibition of LSD1 and Upregulation of H3K4 Methylation. Biomolecules, 2023, 13, 521.	1.8	2
338	Comprehensive analysis reveals the value of the expression of chromobox family members for bladder urothelial carcinoma prognosis. Oncology Letters, 2023, 25, .	0.8	2
339	An m7C-related lncRNA signature predicts prognosis and reveals the immune microenvironment in bladder cancer. Scientific Reports, 2023, 13, .	1.6	0

#	ARTICLE	IF	CITATIONS
340	The autocrine glycosylated-GREM1 interacts with TGFB1 to suppress TGF β 2/BMP/SMAD-mediated EMT partially by inhibiting MYL9 transactivation in urinary carcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2023, 46, 933-951.	2.1	2
341	Noninvasive Detection of Bladder Cancer Markers Based on Gold Nanomushrooms and Sandwich Immunoassays. <i>ACS Applied Nano Materials</i> , 2023, 6, 5557-5567.	2.4	1
342	Screening ANLN and ASPM as bladder urothelial carcinoma-related biomarkers based on weighted gene co-expression network analysis. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
343	The Regulatory Role of Nuclear Respiratory Factor 1 in Bladder Cancer Cells. <i>Anticancer Research</i> , 2023, 43, 1521-1531.	0.5	1
344	Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
345	Nutrient Patterns and Bladder Cancer: A Case-Control Study in Iran. <i>Nutrition and Cancer</i> , 2023, 75, 1323-1329.	0.9	0
346	A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	0
347	Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging. <i>BMC Medicine</i> , 2023, 21, .	2.3	2
348	Comprehensive analysis of a novel RNA modifications-related model in the prognostic characterization, immune landscape and drug therapy of bladder cancer. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
349	Androgen Receptor Transcriptionally Inhibits Programmed Death Ligand-1 Expression and Influences Immune Escape in Bladder Cancer. <i>Laboratory Investigation</i> , 2023, 103, 100148.	1.7	1
350	The androgen receptor in bladder cancer. <i>Nature Reviews Urology</i> , 2023, 20, 560-574.	1.9	5
351	Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data. <i>Pathology and Oncology Research</i> , 0, 29, .	0.9	1
393	Urothelkarzinom der Harnblase: Epidemiologie, Ätiologie und Risikofaktoren. <i>Springer Reference Medizin</i> , 2023, , 763-769.	0.0	0
444	Current and Potential Roles of Ferroptosis in Bladder Cancer. <i>Current Medical Science</i> , 2024, 44, 51-63.	0.7	0
461	Comparison of morbidity and mortality after radical cystectomy between individuals older and younger than 80 years: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 0, , .	0.6	0
467	Systemic anticancer therapy for urothelial carcinoma: UK oncologists's perspective. <i>British Journal of Cancer</i> , 2024, 130, 897-907.	2.9	0